University of Cantabria
If you are the contact person for this centre and you wish to make any changes, please contact us.
Full Professor of Prehistory and Director of the EvoAdapta Group at the University of Cantabria
Head of the Neurology Department at the Marqués de Valdecilla-IDIVAL University Hospital and Associate Professor of Medicine in the Department of Medicine and Psychiatry at the University of Cantabria
Professor of the Department of Physiology and Pharmacology at the University of Cantabria.
Professor of Pharmacology at the University of Cantabria and President of the Ibero-American Down21 Foundation
PhD in Physics and tenured scientist at the Institute of Physics of Cantabria (CSIC-UC)
Scientific Director of the Valdecilla Health Research Institute (IDIVAL) and Professor of Immunology at the University of Cantabria
Associate Professor in the Department of Education at the University of Cantabria
An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.
The DIAN-TU platform is an initiative to test Alzheimer's disease treatments early, by recruiting people with a mutation that leads to developing the disease in the future. One of the trials with the anti-amyloid drug gantenerumab ended without reaching the targets. However, a continuation of the study in 73 patients suggests - for the first time, according to the authors - that long-term, high-dose treatment given some time before symptoms develop could delay the onset of the disease. The results are published in the journal The Lancet Neurology.
Patients receiving organ transplants often need to be treated with long-term immunosuppressants to reduce the likelihood of rejection, which has numerous side effects. An international team has shown in crab macaque monkeys that, in the case of heart transplantation, the use of these drugs could be avoided if combined with a kidney transplant from the same donor. The results are published in the journal Science Translational Medicine.
A team of researchers has analyzed more than 300 human genomes from the last 50,000 years and has concluded that most of the gene flow we received from Neanderthals is attributable to a single period, which probably occurred between 50,500 and 43,500 years ago. In addition, Neanderthal inheritance underwent rapid natural selection in subsequent generations, especially on the X chromosome, according to a study published in Science.
At least two hominin species - Homoerectus and Paranthropus boisei- coexisted in Kenya's Turkana Basin around 1.5 million years ago, a study published in Science confirms. The authors describe the first physical evidence of this coexistence in the form of footprints, found at several sites in the area.
A study by Italian researchers has tested a treatment administered as a nasal spray to slow down early-stage Alzheimer's disease. Administered in mice, the treatment inhibits an enzyme linked to the disease and to insulin resistance. According to the researchers, who publish the work in the journal PNAS, application of the spray to the animals “can counteract the accumulation of harmful proteins in neurons and delay the onset and progression of cognitive decline”.
The Royal Swedish Academy of Sciences has awarded the Nobel Prize in Physics 2024 to researchers John J. Hopfield and Geoffrey E. Hinton for discovering the foundations that enable machine learning with artificial neural networks. Hinton for discovering the foundational basis that enables machine learning with artificial neural networks. This technology, inspired by the structure of the brain, is behind what we now call ‘artificial intelligence’.
Newborns with Down syndrome, as they grow, face a higher risk of developing leukemia compared to those without the syndrome. An international team has sequenced the genes of more than 1.1 million cells from fetuses with and without Down syndrome, and it has discovered that the extra chromosome 21 they have alters the way DNA is packaged inside cells. According to the authors, whose research is published in Nature, this difference affects the regulation of certain genes and may contribute to the development of leukemia.
The European Medicines Agency (EMA) has recommended not granting marketing authorization for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease. The EMA's Committee for Medicinal Products for Human Use (CHMP) considers that its effect in delaying cognitive decline does not outweigh the risk of serious side effects associated with the drug, in particular swelling and possible bleeding in patients' brains. Leqembi™ was approved in 2023 in the United States.
A family of more than 1,000 members with origins in Colombia has a mutation called "paisa" that leads to the development of Alzheimer's disease. In 2019, an added mutation in the apoE gene called "Christchurch" was described as conferring strong protection to an individual carrying two copies of it. Now, a study has found that 27 family members carry a single copy and that it is also associated with some degree of protection. According to the authors, who publish their findings in the journal NEJM, the discovery could be used to develop new treatments for the disease.